يبحث (أخبار)

Revolution Medicines To Present Updated Phase 1 Clinical Data For Zoldonrasib In Patients With Previously Treated KRAS G12D Non-Small Cell Lung Cancer At The 2026 AACR Annual Meeting

health top

(MENAFN - GlobeNewsWire - Nasdaq) REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted ...
2026-04-19 14:01:13